Product details

In May 2022, the chief executive officer (CEO) of Pfizer Inc (Pfizer), Albert Bourla, announced an initiative called 'An Accord for a Healthier World' to supply less-developed countries with the company's COVID-19 vaccine Comirnaty and the oral antiviral drug Paxlovid. The program sought to reach 1.2 billion people in 45 countries with a focus on treating diseases that disproportionately affected low-income countries. The initiative was part of the company's goal to reduce the number of people around the world who could not afford their medicines by 50 per cent. Bourla's plan was to reach that goal by 2023. The move was in response to criticism that Pfizer was not doing enough to get vaccines to people in less-developed countries. The CEO acknowledged the challenges of distribution, such as poor infrastructure, misinformation, and corruption and stated that solutions should address these underlying problems, rather than focusing on the cost of vaccines. He also stated that a vaccine patent waiver would not be effective because other countries did not have the necessary infrastructure or knowledge to safely produce high-quality vaccines. The waiver would also set a precedent for future endeavours, potentially making manufacturers reluctant to develop new treatments. However, how could Pfizer effectively communicate its efforts to address global health inequities?